Fortrea Holdings Inc. (NASDAQ:FTRE) is a top pick for the next 5 years, with Barclays raising its price target to $8 and a strong Q2 performance. Quarterly revenue hit $710.3 million, up 7.23% YoY, leading to an Adjusted EBITDA of $54.9 million.

Despite growth, Fortrea reported a GAAP net loss of $374.9 million in Q2 due to a non-cash charge. The company’s backlog is $7.547 billion, and cost-saving initiatives are on track. Fortrea is a contract research organization serving biopharmaceutical and medical device customers.

While FTRE offers investment potential, some AI stocks may have greater upside. A free report highlights an undervalued AI stock poised to benefit from tariffs and onshoring trends. For more stock insights, check out “30 Stocks That Should Double in 3 Years” and “11 Hidden AI Stocks to Buy Right Now.”

Read more at Yahoo Finance: Barclays Lifts Fortrea (FTRE) PT to $8 Amid Q3 2025 Life Sciences Preview